i~HD is a partner in the new EU research project HIPPOCRATES which seeks to promote early identification and to improve outcomes for patients with psoriatic arthritis.
By looking into the disease mechanisms of psoriatic arthritis, the 26 European partners collaborating in HIPPOCRATES aim at improving diagnostic and therapeutic options for patients living with this condition. Through gaining a better understanding of the complex interplay between clinical and environmental factors, genotype and molecular pathways, the team aims to enable earlier diagnosis and a more accurate prediction of disease progression. This will revolutionise treatment and deliver profound patient benefits.
Data management
In order to achieve its goals, the HIPPOCRATES project will set up a single integrated database combining the cohorts and datasets of the most important European PsA studies and establish a Europe-wide library of relevant clinical biosamples. HIPPOCRATES will also establish a large, prospective, observational study of 25,000 patients with psoriasis who will be recruited and followed on-line for development of PsA.
i~HD has responsibility for ensuring robust data protection, data management and FAIR data sharing.
About psoriatic arthritis
Psoriatic arthritis (PsA) is a chronic immune-mediated inflammatory disease that affects joints and other components of the musculoskeletal system, together with skin involvement, in an estimated 5-10 million individuals in the EU. The symptoms of the disease, including pain, joint stiffness and fatigue, can impact on many aspects of life including function and productivity.
About the project
The HIPPOCRATES partners contribute a diverse range of backgrounds including clinical, scientific, data analytics, ethics, patient participation as well as SME and pharmaceutical industry expertise. The project runs for a period of five years, starting in June 2021, with a total budget of EUR 21 million provided by the Innovative Medicines Initiative (IMI 2), a Joint Undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
